Chad Hatfield, Pharm.D., of UC Davis Health, says 340B savings fund free clinics and mental health care that could shrink as the program’s future shifts.
|Articles|July 1, 2006
HMO pharmacy copay comparison
Appropriate benefit design-copay structures and tiers-is an important factor in providing members and patients with access to treatment that is affordable. Meanwhile, cost sharing with consumers continues to increase because of pressures on maintaining competitive premium costs and the lack of innovative means to manage utilization, say experts.
Advertisement
Advertisement
Related to this article
Fewer than 1 in 5 eligible adults get lung cancer screening. Experts told MHE over email that health plans can help by easing cost, coverage and approval barriers.
Healthcare spending for employer-insured Americans rose by nearly 19%between 2019 and 2023, driven by higher prices, surging drug costs, and spending on hospital care, says the president and CEO of the Health Care Cost Institute.
All 46 people with HIV who started long-acting lenacapavir and cabotegravir at a University of California, San Francisco, clinic reached or kept viral suppression over a median of 100 weeks.
Luis Garza, M.D., Ph.D., a Johns Hopkins professor, says hidradenitis suppurativa is neither an infection nor a classic autoimmune disease but an auto-inflammatory condition.
Vision impairment affected 17.6% of 1,484 adult burn survivors in a study presented at AAO 2026, with age the strongest predictor of difficulty seeing.
During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.
Hidradenitis suppurativa is becoming more common, and a Johns Hopkins expert suspects an unidentified chemical in processed foods may be one reason.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Long-acting lenacapavir plus cabotegravir kept all 46 patients with HIV virally suppressed in recent trial
2
Chronic hand eczema needs more than topical steroids | Fall Clinical Derm 2026
3
Chad Hatfield, Pharm.D., on the 340B uncertainty facing health systems| HSES 2026
4
Why biosimilars keep losing ground to brand-name rivals: A Q&A with Christine Johnston, MBA
5